Fuda Cancer Hospital
| 中国 | トルコ | オーストリア | |
| 高密度焦点式超音波焼灼術 | から $10,500 | から $4,000 | から $12,000 |
| 陽子線治療 | から $36,500 | から $70,000 | から $80,000 |
| 陽子線治療 | から $42,500 | から $30,000 | から $80,000 |
| 放射線療法 | から $10,500 | から $3,250 | から $18,000 |
| 大腸癌に対する放射線療法 | から $11,500 | から $7,000 | から $12,000 |
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
First-line treatment for Leiomyosarcoma in China prioritizes complete surgical resection with negative margins for localized tumors. Advanced cases utilize anthracycline-based chemotherapy. Chinese protocols uniquely integrate domestic multi-kinase inhibitors like anlotinib alongside standard systemic therapies. Tertiary hospitals often provide precision technologies like CyberKnife or proton therapy.
Bookimed Expert Insight: China's oncology landscape offers a unique high-volume advantage for complex cases. Xiamen Humanity Hospital alone serves 1,000,000 patients annually. Large tertiary centers like Fuda Cancer Hospital utilize specialized interventions like cryosurgery and NanoKnife. This high throughput ensures surgeons maintain proficiency in rare soft tissue malignancies.
Patient Consensus: Patients emphasize finding a specialized sarcoma surgeon initially to avoid poor first operations. They note that pathology results often change after expert review at major tertiary hospitals.
China manages uterine leiomyosarcoma (uLMS) through aggressive surgical protocols and advanced precision medicine research. Treatment centers focus on secondary cytoreductive surgery for recurrences. They also integrate AI-driven pathology to counteract high rates of initial surgical misdiagnosis. Most facilities utilize multi-omics subtyping to predict chemotherapy responses.
Bookimed Expert Insight: China's oncology infrastructure is uniquely divided between high-volume tertiary centers and smaller local hospitals. Data shows Xiamen Humanity Hospital serves approximately 1,000,000 patients annually. Large-scale institutions like this are essential for rare diseases like uLMS. They provide the necessary volume to support clinical trials and advanced technologies like CyberKnife M6. Smaller hospitals may not offer the same diagnostic precision for sarcoma.
Patient Consensus: Patients note it is important to avoid tissue fragmentation during surgery if sarcoma is suspected. They emphasize seeking expert pathology reviews at major academic centers to ensure the correct treatment plan.
Leading Chinese oncology centers for Leiomyosarcoma include Fuda Cancer Hospital and Xiamen Humanity Hospital. These facilities specialize in multidisciplinary care for rare soft-tissue sarcomas. They integrate JCI-accredited safety standards with advanced minimally invasive technologies like NanoKnife and precision radiation to optimize patient outcomes.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in China. Xiamen Humanity Hospital treats approximately 1,000,000 patients annually. This high throughput ensures medical teams maintain expertise in rare pathologies like Leiomyosarcoma. Smaller clinics may lack the required multidisciplinary depth for complex resections.
Patient Consensus: Patients emphasize that securing a sarcoma-specific pathologist for the initial review is vital. They recommend choosing high-volume centers in major hubs to ensure surgeons have routine experience with rare soft-tissue tumors.
Chinese oncology centers provide advanced leiomyosarcoma treatments like vascular interventional therapy, CyberKnife M6 radiosurgery, and cryosurgery when chemotherapy fails. Facilities focus on precision destruction of tumors using NanoKnife or microwave hyperthermia. Specialized protocols often include anti-angiogenic TKIs like Apatinib to restrict tumor blood supply.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out for its massive scale, treating 1,000,000 patients annually with 47 clinical departments. This high volume often translates to faster access for clinical drug trials. Patients should prioritize clinics like this when seeking Phase I–IV academic trials for refractory sarcomas. Professor Liu Shi Xin at Xiamen is a national expert in precision radiotherapy, which is vital for late-stage local control.
Patient Consensus: Patients emphasize that full molecular profiling is essential before starting new treatments to find actionable targets. Many note that high-volume university hospitals are often more willing to coordinate combined radiation and systemic therapy rapidly.
China hosts active immunotherapy trials and combination therapies for leiomyosarcoma (LMS). Research focuses on pairing PD-1 inhibitors with anti-angiogenic agents, targeted therapies, or epigenetic regulators. These approaches help penetrate cold tumors. Major oncology centers in Guangzhou and Xiamen facilitate these advanced protocols.
Bookimed Expert Insight: Patient volume deeply impacts trial access in China. Xiamen Humanity Hospital serves approximately 1,000,000 patients annually. This massive scale often correlates with accreditation for Phase I-IV drug trials. Large-scale tertiary hospitals are more likely to offer these experimental combination protocols than smaller oncology clinics.
Patient Consensus: Patients note that immunotherapy is rarely used alone for LMS. Most discussions focus on finding specific trials that combine checkpoint inhibitors with targeted treatments or regional protocols.
Traditional Chinese Medicine serves as a supportive care layer alongside conventional surgery, radiation, and chemotherapy. Integrated protocols focus on managing treatment side effects like nausea and fatigue. It optimizes constitutional health and systemic recovery without replacing definitive oncological interventions for sarcoma.
Bookimed Expert Insight: Patients should note that leading Chinese centers like Xiamen Humanity Hospital and Fuda Cancer Hospital emphasize clinical trials and advanced technologies like NanoKnife alongside traditional roots. The most effective strategy involves securing a precise diagnosis and surgical plan at these high-volume tertiary hospitals before layering in TCM for recovery. This ensures aggressive sarcoma care remains the primary focus while utilizing traditional methods for long-term well-being.
Patient Consensus: Patients emphasize that TCM should be used to feel better during recovery rather than to shrink tumors. They strongly advise informing the oncology team about all herbal supplements to avoid interactions with anesthesia or chemotherapy.